This is a summary of the European public assessment report (EPAR) for Kanuma. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Kanuma. For practical information about using Kanuma, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Kanuma is indicated for long-term enzyme replacement therapy (ERT) in patients of all ages with lysosomal acid lipase (LAL) deficiency.
Therapeutic Area (MeSH)
ATC Code
A16
ATC Item
其它消化道和代谢药物
Pharmacotherapeutic Group
Other alimentary tract and metabolism products
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| sebelipase alfa | N/A | Sebelipase alfa |
EMA Name
Kanuma
Medicine Name
Kanuma
Aliases
N/ANo risk management plan link.
